Pfizer Inc. $PFE Shares Acquired by Marble Harbor Investment Counsel LLC

Marble Harbor Investment Counsel LLC boosted its holdings in shares of Pfizer Inc. (NYSE:PFE) by 13.4% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 445,948 shares of the biopharmaceutical company’s stock after purchasing an additional 52,827 shares during the period. Pfizer makes up approximately 1.2% of Marble Harbor Investment Counsel LLC’s holdings, making the stock its 28th biggest position. Marble Harbor Investment Counsel LLC’s holdings in Pfizer were worth $11,104,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also added to or reduced their stakes in the company. Horizon Financial Services LLC lifted its stake in Pfizer by 174.8% during the fourth quarter. Horizon Financial Services LLC now owns 1,014 shares of the biopharmaceutical company’s stock valued at $25,000 after purchasing an additional 645 shares during the last quarter. YANKCOM Partnership acquired a new stake in Pfizer during the fourth quarter valued at approximately $28,000. Grey Fox Wealth Advisors LLC acquired a new stake in Pfizer during the third quarter valued at approximately $29,000. HFM Investment Advisors LLC lifted its stake in Pfizer by 61.0% during the fourth quarter. HFM Investment Advisors LLC now owns 1,127 shares of the biopharmaceutical company’s stock valued at $28,000 after purchasing an additional 427 shares during the last quarter. Finally, Darwin Wealth Management LLC purchased a new stake in shares of Pfizer during the second quarter valued at $32,000. 68.36% of the stock is owned by institutional investors and hedge funds.

Pfizer Stock Up 1.3%

Shares of Pfizer stock opened at $25.66 on Wednesday. The stock has a 50-day moving average price of $26.93 and a 200 day moving average price of $26.21. The company has a market cap of $146.27 billion, a P/E ratio of 19.59 and a beta of 0.35. The company has a current ratio of 1.25, a quick ratio of 0.94 and a debt-to-equity ratio of 0.67. Pfizer Inc. has a 1 year low of $22.81 and a 1 year high of $28.75.

Pfizer (NYSE:PFE) last announced its quarterly earnings data on Tuesday, May 5th. The biopharmaceutical company reported $0.75 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.72 by $0.03. The firm had revenue of $14.45 billion during the quarter, compared to the consensus estimate of $13.84 billion. Pfizer had a return on equity of 19.44% and a net margin of 11.83%.The business’s revenue for the quarter was up 5.4% on a year-over-year basis. During the same period in the prior year, the business earned $0.92 EPS. Pfizer has set its FY 2026 guidance at 2.800-3.000 EPS. As a group, analysts expect that Pfizer Inc. will post 2.99 EPS for the current fiscal year.

Pfizer Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, June 12th. Investors of record on Friday, May 8th will be paid a $0.43 dividend. This represents a $1.72 annualized dividend and a yield of 6.7%. The ex-dividend date of this dividend is Friday, May 8th. Pfizer’s dividend payout ratio is currently 131.30%.

Wall Street Analyst Weigh In

Several brokerages have recently commented on PFE. Barclays began coverage on Pfizer in a report on Thursday, February 19th. They set an “underweight” rating and a $25.00 target price for the company. Bank of America reduced their target price on Pfizer from $27.00 to $26.00 and set a “neutral” rating for the company in a report on Thursday, April 9th. Wall Street Zen raised Pfizer from a “hold” rating to a “buy” rating in a report on Saturday, May 9th. Citigroup upped their target price on Pfizer from $26.00 to $27.00 and gave the company a “neutral” rating in a report on Wednesday, April 29th. Finally, CICC Research started coverage on shares of Pfizer in a research report on Thursday, April 16th. They issued an “outperform” rating and a $33.00 price target for the company. One analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating, twelve have assigned a Hold rating and three have issued a Sell rating to the company. According to MarketBeat, Pfizer presently has a consensus rating of “Hold” and an average target price of $28.84.

Key Stories Impacting Pfizer

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: Pfizer launched a new Phase 3 endometrial cancer trial, signaling continued investment in its oncology pipeline and a potential long-term growth driver. Pfizer Takes Aim at Merck in New Phase 3 Endometrial Cancer Trial
• Positive Sentiment: Several recent opinion pieces argued that Pfizer still looks undervalued, which may be supporting bargain-hunting interest in the stock. Why Pfizer Stock Still Looks Deeply Undervalued In 2026
• Positive Sentiment: Technical commentary noted Pfizer’s RSI moved above 50, which traders often read as a sign of improving momentum. Tata Motors PV among 6 stocks showing bullish RSI upswing
• Neutral Sentiment: Analyst coverage remained unchanged at “Hold,” suggesting the market still sees Pfizer as fairly valued despite recent catalysts. Pfizer Inc. (NYSE:PFE) Receives Consensus Recommendation of “Hold” from Analysts
• Negative Sentiment: Pfizer and other big drugmakers came under pressure after reports that the TrumpRx drug-pricing initiative may be set for “dramatic expansion,” reviving policy overhang concerns for the sector. PFE, NVO, LLY: Pharma Stocks Drop on News TrumpRx Set for ‘Dramatic Expansion’

About Pfizer

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.